Shortly thereafter, immune checkpoint PD-1/PD-1L inhibitors were approved starting in 2014 for a variety of cancers including lung cancer, kidney cancer, urothelial cancer, Hodgkin's disease, breast cancer (13), as well as for microsatellite high and mismatch repair deficient solid tumors (14). Here, PDCD1 is linked to Hodgkins lymphoma.